PDS Biotechnology Closes $6M Debt Financing and Establishes $50M ATM Offering Program

On June 15, 2026, PDS Biotechnology Corporation closed a Securities Purchase Agreement with YA II PN, LTD. (the Investor), issuing a $6.0 million promissory note and a warrant to purchase approximately 2.16 million shares of common stock at an exercise price of $1.1824 per share. The promissory note was issued at a 4% discount for $5.76 million, carries a 10% annual interest rate, and matures in 12 months. Concurrently, the company entered into a Sales Agreement with Yorkville Securities and B. Riley Securities for an at-the-market (ATM) offering program, allowing the company to sell up to $50.0 million in common stock at its discretion. Proceeds from the ATM program will primarily be used to service amortization payments on the new promissory note, with remaining funds allocated for working capital. In connection with this new financing, PDS Biotechnology repaid in full and terminated its previous senior secured convertible debentures originally issued in April 2025. B. Riley Securities is acting as a qualified independent underwriter for the ATM offering.